blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2070539

EP2070539 - Combinations of a derivative of 8-[3-amino-piperidin-1-yl]-xanthin and a second active ingredient and their use for treating diabetes [Right-click to bookmark this link]
Former [2009/25]8-[3-amino-piperidin-1-yl]-xanthins, their production and utilisation as medicine
[2013/23]
StatusThe application is deemed to be withdrawn
Status updated on  22.01.2016
Database last updated on 15.06.2024
Most recent event   Tooltip22.01.2016Application deemed to be withdrawnpublished on 24.02.2016  [2016/08]
Applicant(s)For all designated states
Boehringer Ingelheim Pharma GmbH & Co. KG
Binger Strasse 173
55216 Ingelheim am Rhein / DE
[2009/25]
Inventor(s)01 / Himmelsbach, Frank
Boehringer Ingelheim Pharma GmbH Co. KG Ahornweg 16
88441 Mittelbiberach / DE
02 / Langkopf, Elke
Boehringer Ingelheim Pharma GmbH Co. KG Schloss 3
88447 Warthausen / DE
03 / Echhardt, Matthias
Boehringer Ingelheim Pharma GmbH Co. KG Kirschenweg 7
88400 Biberach / DE
04 / Mark, Michael
Boehringer Ingelheim Pharma GmbH Co. KG Hugo-Haering-Str. 50
88400 Biberach / DE
05 / Maier, Roland
Boehringer Ingelheim Pharma GmbH Co. KG Bodelschwinghstr. 39
88400 Biberach / DE
06 / Lotz, Ralf
Boehringer Ingelheim Pharma GmbH Co. KG Schluesslerstr. 28
88433 Schemmerhofen / DE
07 / Tadayyon, Mohammad
Boehringer Ingelheim Pharma GmbH & Co. KG 6, Bridges Court, St. Andrew Street
Hertford SG14 1HQ / GB
 [2009/25]
Representative(s)Simon, Elke Anna Maria, et al
Boehringer Ingelheim GmbH
Binger Strasse 173
55216 Ingelheim am Rhein / DE
[2012/40]
Former [2009/48]Hammann, Heinz
Boehringer Ingelheim GmbH CD-Patents Binger Straße 173
55216 Ingelheim am Rhein / DE
Former [2009/25]Hammann, Heinz
Boehringer Ingelheim GmbH Binger Strasse 173
55216 Ingelheim am Rhein / DE
Application number, filing date08159141.418.08.2003
[2009/25]
Priority number, dateDE200213824321.08.2002         Original published format: DE 10238243
DE200311235320.03.2003         Original published format: DE 10312353
[2009/25]
Filing languageDE
Procedural languageDE
PublicationType: A1 Application with search report 
No.:EP2070539
Date:17.06.2009
Language:DE
[2009/25]
Search report(s)(Supplementary) European search report - dispatched on:EP19.05.2009
ClassificationIPC:A61P3/10, A61K9/02, A61K9/20, A61K9/28, A61K9/48, A61K9/00, A61K47/02
[2013/23]
CPC:
A61K9/2866 (EP); C07D473/04 (EP,CN,KR); A61K47/02 (EP);
A61K9/0095 (EP); A61K9/02 (EP); A61K9/2018 (EP);
A61K9/4858 (EP); A61P1/02 (EP); A61P1/04 (EP);
A61P1/18 (EP); A61P11/00 (EP); A61P13/08 (EP);
A61P13/12 (EP); A61P15/00 (EP); A61P15/08 (EP);
A61P15/16 (EP); A61P17/00 (EP); A61P17/06 (EP);
A61P19/00 (EP); A61P19/02 (EP); A61P19/08 (EP);
A61P19/10 (EP); A61P25/00 (EP); A61P25/06 (EP);
A61P25/16 (EP); A61P25/22 (EP); A61P25/24 (EP);
A61P25/28 (EP); A61P27/02 (EP); A61P29/00 (EP);
A61P3/00 (EP); A61P3/04 (EP); A61P3/06 (EP);
A61P3/08 (EP); A61P3/10 (EP); A61P3/12 (EP);
A61P31/10 (EP); A61P31/12 (EP); A61P31/18 (EP);
A61P35/00 (EP); A61P35/02 (EP); A61P35/04 (EP);
A61P37/06 (EP); A61P43/00 (EP); A61P5/06 (EP);
A61P5/14 (EP); A61P7/00 (EP); A61P7/10 (EP);
A61P9/10 (EP); A61P9/12 (EP); C07D473/06 (CN);
C07D473/12 (KR) (-)
Former IPC [2009/25]A61K31/522, A61P3/10
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   RO,   SE,   SI,   SK,   TR [2009/25]
Extension statesLT17.12.2009
LV17.12.2009
TitleGerman:Kombinationen aus einem 8-(3-Aminopiperidin)xanthin-Derivat und einem zweiten Wirkbestandteil un deren Verwendung für die Behandlung von Diabetes[2013/23]
English:Combinations of a derivative of 8-[3-amino-piperidin-1-yl]-xanthin and a second active ingredient and their use for treating diabetes[2013/23]
French:Combinaisons d'un dérivé de 8-[3-amino-pipéridine-1-yl]-xanthine et d'un second principe actif et leur utilisation pour traiter le diabète[2013/23]
Former [2009/25]8-[3-Amino-Piperidin-1-YL]-Xanthine, deren Herstellung und deren Verwendung als Arzneimittel
Former [2009/25]8-[3-amino-piperidin-1-yl]-xanthins, their production and utilisation as medicine
Former [2009/25]8-[3-amino-pipéridine-1-yl]-xanthine, leur fabrication et leur utilisation en tant que médicament
Examination procedure17.12.2009Examination requested  [2010/04]
01.02.2010Despatch of a communication from the examining division (Time limit: M06)
11.08.2010Reply to a communication from the examining division
13.02.2012Despatch of a communication from the examining division (Time limit: M04)
25.06.2012Reply to a communication from the examining division
29.04.2013Cancellation of oral proceeding that was planned for 30.04.2013
30.04.2013Date of oral proceedings (cancelled)
14.06.2013Communication of intention to grant the patent
24.10.2013Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
21.11.2013Communication of intention to grant the patent
03.03.2015Despatch of a communication from the examining division (Time limit: M06)
15.09.2015Application deemed to be withdrawn, date of legal effect  [2016/08]
12.10.2015Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2016/08]
Parent application(s)   TooltipEP03792359.6  / EP1532149
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20030792359) is  27.10.2005
Fees paidRenewal fee
27.10.2008Renewal fee patent year 03
27.10.2008Renewal fee patent year 04
27.10.2008Renewal fee patent year 05
27.10.2008Renewal fee patent year 06
31.08.2009Renewal fee patent year 07
31.08.2010Renewal fee patent year 08
31.08.2011Renewal fee patent year 09
31.08.2012Renewal fee patent year 10
02.09.2013Renewal fee patent year 11
01.09.2014Renewal fee patent year 12
31.08.2015Renewal fee patent year 13
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[Y]WO0152825  (NOVARTIS AG [CH], et al) [Y] 1-21* the whole document *;
 [Y]WO0197808  (SMITHKLINE BEECHAM PLC [GB], et al) [Y] 1-21 * the whole document *;
 [Y]WO0202560  (NOVO NORDISK AS [DK], et al) [Y] 1-21 * Ansprüche 1-53; Formel (I); Seite 40, Zeile 1-25 *;
 [PX]WO02068420  (BOEHRINGER INGELHEIM PHARMA [DE], et al) [PX] 1,2 * Ansprüche 1-18; Formel (I); Verbindungen (344),(471), (343), (439), (136), (528), (521), (520), (444), (524), (368), (525), (329)-(333), (361), (523), (482), (428), (138) und (469); Seite 106, Zeile 14-32 *;
 [PX]WO03004496  (NOVO NORDISK AS [DK]) [PX] 1-21 * Ansprüche 1-55; Formel (I); Beispiele 1,9-10,16-74,87-103; Seite 22, Zeile 1-28 *;
 [PX]WO03057200  (NOVO NORDISK AS [DK], et al) [PX] 1-21 * Ansprüche 1-18; Formel (I); Beispiele 1,9-10; Seite 8, Zeile 24 - Seite 9, Zeile 35 *
by applicantWO9846576
    - VON N.M. NIELSEN ET AL., INTERNATIONAL JOURNAL OF PHARMACEUTICS, (1987), vol. 39, pages 75 - 85
    - ALLINGER N. L.; ELIEL E. L., Topics in Stereochemistry, WILEY INTERSCIENCE, (1971), vol. 6
    - BESCHREIBUNG VON REIHER ET AL., "Increased expression of intestinal cell line Caco-2", PROC. NATL. ACAD. SCI., (1993), vol. 90, pages 5757 - 5761
    - KIMURA ET AL., CHEM. PHARM. BULL., (1982), vol. 30, pages 552 - 558
    - R. BESSE ET AL., TETRAHEDRON, (1990), vol. 46, pages 7803 - 7812
    - VON GONSALVES ET AL., TETRAHEDRON, (1992), vol. 48, page 6821
    - SAGI ET AL., HETEROCYCLES, (1989), vol. 29, page 2253
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.